Wells Fargo & Company Has Lowered Expectations for iRhythm Technologies (NASDAQ:IRTC) Stock Price

iRhythm Technologies (NASDAQ:IRTC) had its price target dropped by equities research analysts at Wells Fargo & Company from $200.00 to $180.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 51.09% from the company’s current price.

Several other equities analysts have also commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of iRhythm Technologies in a research report on Tuesday, April 21st. Needham & Company LLC boosted their price target on iRhythm Technologies from $254.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group reduced their price target on iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Evercore raised iRhythm Technologies from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $194.00 to $210.00 in a research report on Monday, January 5th. Finally, Robert W. Baird reduced their price target on iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating on the stock in a research report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $202.23.

iRhythm Technologies Stock Down 7.8%

iRhythm Technologies stock traded down $10.02 during midday trading on Friday, hitting $119.14. 188,693 shares of the company were exchanged, compared to its average volume of 618,252. The company’s fifty day moving average price is $122.93 and its 200-day moving average price is $154.60. The company has a market cap of $3.91 billion, a PE ratio of -84.79 and a beta of 1.18. The company has a debt-to-equity ratio of 4.25, a current ratio of 4.63 and a quick ratio of 4.48. iRhythm Technologies has a fifty-two week low of $112.31 and a fifty-two week high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.31. The firm had revenue of $199.39 million for the quarter, compared to analyst estimates of $194.11 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.iRhythm Technologies’s revenue for the quarter was up 25.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.97) EPS. On average, research analysts predict that iRhythm Technologies will post -0.16 EPS for the current fiscal year.

Insider Activity at iRhythm Technologies

In other iRhythm Technologies news, insider Patrick Michael Murphy sold 4,357 shares of iRhythm Technologies stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.44, for a total transaction of $559,613.08. Following the sale, the insider directly owned 63,203 shares in the company, valued at $8,117,793.32. The trade was a 6.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sumi Shrishrimal sold 2,830 shares of iRhythm Technologies stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.44, for a total value of $363,485.20. Following the sale, the executive vice president owned 41,870 shares in the company, valued at $5,377,782.80. This represents a 6.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 94,509 shares of company stock worth $12,734,195 over the last ninety days. Company insiders own 1.10% of the company’s stock.

Institutional Investors Weigh In On iRhythm Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. increased its holdings in shares of iRhythm Technologies by 45.4% in the 3rd quarter. Federated Hermes Inc. now owns 70,401 shares of the company’s stock valued at $12,108,000 after acquiring an additional 21,977 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of iRhythm Technologies by 30.1% in the 3rd quarter. Victory Capital Management Inc. now owns 77,952 shares of the company’s stock valued at $13,407,000 after acquiring an additional 18,053 shares during the last quarter. Cookson Peirce & Co. Inc. increased its holdings in shares of iRhythm Technologies by 105.4% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 14,524 shares of the company’s stock valued at $2,498,000 after acquiring an additional 7,452 shares during the last quarter. Jain Global LLC bought a new stake in shares of iRhythm Technologies in the 3rd quarter valued at approximately $22,547,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of iRhythm Technologies in the 3rd quarter valued at approximately $3,439,800,000.

Key Stories Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 results beat expectations: iRhythm reported EPS of ($0.35) vs. consensus ($0.66) and revenue of $199.4M (vs. $194.1M est.), with revenue up ~25.6% YoY — this shows improving top-line momentum and narrower losses. MarketBeat Q1 results
• Positive Sentiment: Analyst bullishness: Needham raised its price target to $255 and kept a Buy rating, signaling strong upside expectations from some sell‑side analysts. Benzinga note on Needham
• Positive Sentiment: Market expansion, margin gains and AI/regulatory tailwinds highlighted in recent coverage — these catalysts could support longer‑term revenue and margin improvement if execution continues. MSN deep dive
• Neutral Sentiment: FY‑2026 revenue guidance was provided (~$875–$885M), which is essentially in line with consensus (~$876M); EPS guidance was unclear in the release — mixed signal that tempers the beat. Company press release / slide deck
• Neutral Sentiment: Full Q1 materials and the earnings call transcript are available for deeper due diligence (useful for evaluating management commentary on margins, utilization and reimbursement). Seeking Alpha transcript
• Negative Sentiment: Not all analysts are upbeat — Truist cut its price target in a healthcare sector preview, reflecting more cautious sentiment that could weigh on near‑term shares. Yahoo/Truist note
• Negative Sentiment: Company remains unprofitable with negative net margin and ROE; investors sensitive to profitability timelines may sell into the beat, keeping pressure on the stock. Zacks coverage

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.